secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2026-08-28T21:25:56+00:00
Accession:  0001193125-26-374788
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero enters $100M ATM facility with Jefferies, terminates Cantor ATM
---------------------------------------------------------------------

- Sale Agreement with Jefferies LLC enables up to $100M of common stock in at-the-market offerings once S-3 is effective.
- Registration statement on Form S-3 for up to $300M in securities filed Aug 28, 2026; not yet effective, no sales permitted until then.
- Jefferies to receive up to 3.0% of gross proceeds for shares sold under the agreement.
- Terminated Cantor Fitzgerald ATM agreement effective Aug 28, 2026; no shares sold under it in FY2024 or FY2025, no penalties incurred.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526374788/0001193125-26-374788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526374788/d145223d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-374788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer